Annual Surveillance Summary: Methicillin-resistant Staphylococcus aureus (MRSA) Infections in the Military Health System (MHS), 2017
Abstract
The EpiData Center (EDC) conducts routine surveillance of methicillin-resistant Staphylococcus aureus (MRSA) incidence and prevalence among all beneficiaries seeking care within the Military Health System (MHS). This report describes demographics, clinical characteristics, prescription practices, and antibiotic resistance patterns observed for MRSA infections in calendar year (CY) 2017. Multiple data sources were linked to assess descriptive and clinical factors related to MRSA. Health Level 7 (HL7)-formatted Composite Health Care System (CHCS) microbiology data identified S. aureus infections resistant to oxacillin, cefoxitin, or methicillin. These infections were matched to HL7-formatted CHCS pharmacy data to assess prescription practices, the Standard Inpatient Data Record (SIDR) to determine healthcare-associated exposures, and the Defense Manpower Data Center (DMDC) rosters to determine burden among Department of Defense (DOD) active duty (AD) service members. Overall, incidence rates (IRs) of MRSA in the MHS beneficiary and DOD AD populations are decreasing. Inducible clindamycin resistance (ICR) is slowly increasing in the MHS, with a 3.7 increase from the weighted historic ICR; no additional changes in antibiotic susceptibility emerged in 2017. Clindamycin, trimethoprim/sulfamethoxazole, doxycycline, and vancomycin remain viable treatments for MRSA, although clindamycin should be used cautiously in the inpatient setting due to reduced susceptibility (less than 85 ). Current infection control practices appear effective, and continued surveillance is recommended.
Document Details
- Document Type
- Technical Report
- Publication Date
- May 01, 2018
- Accession Number
- AD1060091
Entities
People
- Jessica R. Spencer
- Uzo Chukwuma
Organizations
- Navy and Marine Corps Public Health Center